Author

M. Saijo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Zoology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Organism:human· 1 Organism:multiple species· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

H. Tani· 4 shared M. Shimojima· 4 shared S. Fukushi· 4 shared S. Morikawa· 4 shared S. Taniguchi· 3 shared A. Fukuma· 2 shared M. Kimura· 2 shared T. Kurosu· 2 shared

Activity by Year

2018-2020 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

H. Tani

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Development of a reverse transcription polymerase chain reaction for the detection of severe fever with thrombocytopenia syndrome virus from suspected infected animals

E.-S. Park, O. Fujita, M. Kimura, A. Hotta, K. Imaoka, M. Shimojima, M. Saijo, K. Maeda, S. Morikawa

This paper develops an RT-PCR assay to detect SFTSV in suspected animals, identifying 5 positive cases among 56 samples and demonstrating its sensitivity and specificity.

bioRxiv · Aug 24, 2020Microbiology

Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein

H. Tani, L. Tan, M. Kimura, Y. Yoshida, H. Yamada, S. Fukushi, M. Saijo, H. Kawasuji, A. Ueno, Y. Miyajima, Y. Fukui, I. Sakamaki, Y. Yamamoto, Y. Morinaga

This study evaluates SARS-CoV-2 neutralizing antibodies using a pseudotyped virus assay and compares results with immunofluorescence assay findings.

bioRxiv · Aug 21, 2020Microbiology

A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome

T. Yoshikawa, S. Taniguchi, H. Kato, N. Iwata-Yoshikawa, H. Tani, T. Kurosu, H. Fujii, N. Omura, M. Shibamura, S. Watanabe, K. Egawa, T. Inagaki, S. Sugimoto, S. Phanthanawiboon, S. Harada, , M. Saijo

This paper develops and tests recombinant vaccinia virus vaccines against SFTS, showing they induce protective immunity and are safe in mice.

bioRxiv · Aug 6, 2020Microbiology

Phylogenetic comparative analyses of the determinants of anti-predator distraction behavior in shorebirds

M. Saijo, N. Kutsukake

The paper investigates factors influencing anti-predator distraction behavior in shorebirds using phylogenetic comparative analyses across 169 species, finding that smaller and solitary species are more likely to exhibit this behavior.

bioRxiv · Jun 7, 2020 · PreprintZoology

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

H. Ohashi, K. Watashi, W. Saso, K. Shionoya, S. Iwanami, T. Hirokawa, T. Shirai, S. Kanaya, Y. Ito, K. S. Kim, K. Nishioka, S. Ando, K. Ejima, Y. Koizumi, T. Tanaka, , T. Wakita

This study identifies a new multidrug combination treatment for COVID-19 using nelfinavir and cepharanthine, showing synergistic antiviral effects and improved disease control.

bioRxiv · Apr 14, 2020 · PreprintMicrobiology

Characterization of the untranslated region of lymphocytic choriomeningitis virus S segment

S. Taniguchi, T. Yoshikawa, M. Shimojima, S. Fukushi, T. Kurosu, H. Tani, A. Fukuma, F. Kato, E. Nakayama, T. Maeki, S. Tajima, C.-K. Lim, H. Ebihara, S. Kyuwa, S. Morikawa, M. Saijo

This study investigates the functional roles of untranslated regions (UTRs) in the LCMV S segment, revealing their involvement in viral replication, transcription, and virulence, with implications for vaccine development.

bioRxiv · May 31, 2019 · PreprintMicrobiology

Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration

H. TANI, T. Komeno, A. Fukuma, S. Fukushi, S. Taniguchi, M. Shimojima, A. Uda, S. Morikawa, N. Nakajima, Y. Furuta, M. Saijo

This study shows that oral favipiravir at 120 or 200 mg/kg/day effectively treats SFTSV infection in IFNAR-/- mice when started within 4 days post-infection, preventing mortality.

bioRxiv · Aug 24, 2018Microbiology